For research use only. Not for therapeutic Use.
FLT3-IN-17（Cat No.:I042898）is an investigational small molecule inhibitor designed to target and inhibit the FLT3 receptor, a key tyrosine kinase involved in hematopoiesis and leukemogenesis. FLT3 mutations, particularly FLT3-ITD, are commonly associated with acute myeloid leukemia (AML) and are linked to poor prognosis. By blocking FLT3 signaling, FLT3-IN-17 aims to inhibit the growth and proliferation of leukemia cells, potentially improving survival rates for patients with FLT3-mutated AML. Ongoing clinical trials are evaluating its safety, efficacy, and therapeutic potential as a targeted treatment for AML and other hematological malignancies.
| CAS Number | 2758999-62-9 |
| Synonyms | N-[3-[2-(4-piperazin-1-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide |
| Molecular Formula | C23H24N6O2S2 |
| Purity | ≥95% |
| IUPAC Name | N-[3-[2-(4-piperazin-1-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide |
| InChI | InChI=1S/C23H24N6O2S2/c1-33(30,31)28-18-4-2-3-16(13-18)20-15-32-21-14-25-23(27-22(20)21)26-17-5-7-19(8-6-17)29-11-9-24-10-12-29/h2-8,13-15,24,28H,9-12H2,1H3,(H,25,26,27) |
| InChIKey | MGKRFMQUFDKUBA-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)NC1=CC=CC(=C1)C2=CSC3=CN=C(N=C32)NC4=CC=C(C=C4)N5CCNCC5 |
